Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Protriptyline
- Accession Number
- DB00344 (APRD00441)
- Type
- Small Molecule
- Groups
- Approved
- Description
Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, protriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Protriptyline may be used for the treatment of depression.
- Structure
Structure for DB00344 (Protriptyline)
- Synonyms
- 3-(5H-dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amine
- 3-(5H-Dibenzo[a,D]cyclohepten-5-yl)-N-methyl-1-propanamine
- 5-(3-Methylaminopropyl)-5H-dibenzo[a,D]cycloheptene
- 7-(3-Methylaminopropyl)-1,2:5,6-dibenzocycloheptatriene
- Amimetilina
- N-Methyl-5H-dibenzo[a,D]cycloheptene-5-propanamine
- N-Methyl-5H-dibenzo[a,D]cycloheptene-5-propylamine
- Protriptilina
- Protriptylin
- Protriptyline
- Protriptylinum
- External IDs
- MK 240 / MK-240
- Product Ingredients
Ingredient UNII CAS InChI Key Protriptyline hydrochloride 44665V00O8 1225-55-4 OGQDIIKRQRZXJH-UHFFFAOYSA-N - Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Triptil Tab 10mg Tablet 10 mg Oral Merck Frosst Canada & Cie, Merck Frosst Canada & Co. 1966-12-31 2001-01-25 Canada 
- Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Protriptyline Hydrochloride Tablet, film coated 5 mg/1 Oral Epic Pharma, LLC 2013-01-09 Not applicable US 
Protriptyline Hydrochloride Tablet, film coated 10 mg/1 Oral Rising Pharmaceuticals 2010-06-11 Not applicable US Protriptyline hydrochloride Tablet, film coated 5 mg/1 Oral Hi Tech Pharmacal Co., Inc. 2013-10-28 Not applicable US Protriptyline Hydrochloride Tablet 10 mg/1 Oral West Ward Pharmaceutical 2008-09-16 Not applicable US Protriptyline Hydrochloride Tablet, film coated 5 mg/1 Oral Rising Pharmaceuticals 2010-06-11 Not applicable US Protriptyline Hydrochloride Tablet, film coated 10 mg/1 Oral Epic Pharma, LLC 2013-01-09 Not applicable US Protriptyline Hydrochloride Tablet 5 mg/1 Oral West Ward Pharmaceutical 2008-09-16 Not applicable US Protriptyline hydrochloride Tablet, film coated 10 mg/1 Oral Hi Tech Pharmacal Co., Inc. 2013-10-28 Not applicable US - International/Other Brands
- Triptil / Vivactil (Odyssey)
- Categories
- Adrenergic Agents
- Adrenergic Uptake Inhibitors
- Antidepressive Agents, Tricyclic
- Benzocycloheptenes
- Central Nervous System Agents
- Central Nervous System Depressants
- Combined Inhibitors of Serotonin/Norepinephrine Reuptake
- Dibenzocycloheptenes
- Membrane Transport Modulators
- Nervous System
- Neurotransmitter Agents
- Neurotransmitter Uptake Inhibitors
- Non-Selective Monoamine Reuptake Inhibitors
- P-glycoprotein/ABCB1 Inhibitors
- Potential QTc-Prolonging Agents
- Psychoanaleptics
- Psychotropic Drugs
- QTc Prolonging Agents
- Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
- Serotonin Modulators
- UNII
- 4NDU154T12
- CAS number
- 438-60-8
- Weight
- Average: 263.3767
Monoisotopic: 263.167399677 - Chemical Formula
- C19H21N
- InChI Key
- BWPIARFWQZKAIA-UHFFFAOYSA-N
- InChI
- InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-10,12-13,19-20H,6,11,14H2,1H3
- IUPAC Name
- methyl(3-{tricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,9,11,13-heptaen-2-yl}propyl)amine
- SMILES
- CNCCCC1C2=CC=CC=C2C=CC2=CC=CC=C12
Pharmacology
- Indication
For the treatment of depression.
- Associated Conditions
- Pharmacodynamics
Protriptyline is a tricyclic antidepressant. It was thought that tricyclic antidepressants work by inhibiting the reuptake of the neurotransmitters norepinephrine and serotonin by nerve cells. However, this response occurs immediately, yet mood does not lift for approximately two weeks. It is now thought that changes occur in receptor sensitivity in the cerebral cortex and hippocampus. The hippocampus is part of the limbic system, a part of the brain involved in emotions. Presynaptic receptors are affected: α1 and β1 receptors are sensitized, α2 receptors are desensitised (leading to increased noradrenaline production). Tricyclics are also known as effective analgesics for different types of pain, especially neuropathic or neuralgic pain. A precise mechanism for their analgesic action is unknown, but it is thought that they modulate anti-pain opioid systems in the CNS via an indirect serotonergic route. They are also effective in migraine prophylaxis, but not in abortion of acute migraine attack. The mechanism of their anti-migraine action is also thought to be serotonergic.
- Mechanism of action
Protriptyline acts by decreasing the reuptake of norepinephrine and serotonin (5-HT).
Target Actions Organism ASodium-dependent noradrenaline transporter inhibitorHuman ASodium-dependent serotonin transporter inhibitorHuman - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
Cumulative urinary excretion during 16 days accounted for approximately 50% of the drug. The fecal route of excretion did not seem to be important.
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
Side effects include anxiety, blood disorders, confusion, decreased libido, dizziness, flushing, headache, impotence, insomnia, low blood pressure, nightmares, rapid or irregular heartbeat, rash, seizures, sensitivity to sunlight, stomach and intestinal discomfort, sedation, hypotension, blurred vision, dry mouth, constipation, urinary retention, postural hypotension, tachycardia, hypertension, ECG changes, heart failure, impaired memory and delirium, and precipitation of hypomanic or manic episodes in bipolar depression. Withdrawal symptoms include gastrointestinal disturbances, anxiety, and insomnia.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
Interacting Gene/Enzyme Allele name Genotype(s) Defining Change(s) Type(s) Description Details Cytochrome P450 2D6 CYP2D6*3 Not Available C allele Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*4 Not Available C allele Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*5 Not Available Whole-gene deletion Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*6 Not Available 1707delT Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*7 Not Available 2935A>C Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*8 Not Available 1758G>T Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*11 Not Available 883G>C Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*12 Not Available 124G>A Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*13 Not Available CYP2D7/2D6 hybrid gene structure Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*14A Not Available 1758G>A Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*15 Not Available 137insT, 137_138insT Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*19 Not Available 2539_2542delAACT Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*20 Not Available 1973_1974insG Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*21 Not Available 2573insC Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*31 Not Available -1770G>A / -1584C>G … show all Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*36 Not Available 100C>T / -1426C>T … show all Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*38 Not Available 2587_2590delGACT Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*40 Not Available 1863_1864ins(TTT CGC CCC)2 Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*42 Not Available 3259_3260insGT Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*44 Not Available 2950G>C Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*47 Not Available 100C>T / -1426C>T … show all Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*51 Not Available -1584C>G / -1235A>G … show all Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*56 Not Available 3201C>T Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*57 Not Available 100C>T / 310G>T … show all Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*62 Not Available 4044C>T Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*68A Not Available -1426C>T / -1235A>G … show all Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*68B Not Available Similar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4. Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*69 Not Available 2988G>A / -1426C>T … show all Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*92 Not Available 1995delC Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*100 Not Available -1426C>T / -1235A>G … show all Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*101 Not Available -1426C>T / -1235A>G … show all Effect Inferred Poor drug metabolizer. Details
Interactions
- Drug Interactions
Drug Interaction Drug group (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE The serum concentration of Protriptyline can be increased when it is combined with (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE. Experimental 1,10-Phenanthroline The serum concentration of Protriptyline can be increased when it is combined with 1,10-Phenanthroline. Experimental 2,5-Dimethoxy-4-ethylamphetamine Protriptyline may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine. Experimental, Illicit 2,5-Dimethoxy-4-ethylthioamphetamine Protriptyline may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine. Experimental 3,4-Dichloroisocoumarin The serum concentration of Protriptyline can be increased when it is combined with 3,4-Dichloroisocoumarin. Experimental 3,4-Methylenedioxyamphetamine Protriptyline may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine. Experimental, Illicit 4-(2-Aminoethyl)Benzenesulfonyl Fluoride The serum concentration of Protriptyline can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride. Experimental 4-Bromo-2,5-dimethoxyamphetamine Protriptyline may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine. Experimental, Illicit 4-Methoxyamphetamine Protriptyline may decrease the antihypertensive activities of 4-Methoxyamphetamine. Experimental, Illicit 7-Nitroindazole The risk or severity of adverse effects can be increased when Protriptyline is combined with 7-Nitroindazole. Experimental 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Protriptyline. Experimental Abediterol The risk or severity of adverse effects can be increased when Protriptyline is combined with Abediterol. Investigational Abiraterone The serum concentration of Protriptyline can be increased when it is combined with Abiraterone. Approved Acenocoumarol Protriptyline may increase the anticoagulant activities of Acenocoumarol. Approved, Investigational Acepromazine The risk or severity of adverse effects can be increased when Protriptyline is combined with Acepromazine. Approved, Vet Approved Aceprometazine The risk or severity of adverse effects can be increased when Protriptyline is combined with Aceprometazine. Approved Acetophenazine The risk or severity of adverse effects can be increased when Protriptyline is combined with Acetophenazine. Approved Adipiplon The risk or severity of adverse effects can be increased when Protriptyline is combined with Adipiplon. Investigational Afatinib The serum concentration of Afatinib can be increased when it is combined with Protriptyline. Approved Agmatine Protriptyline may decrease the antihypertensive activities of Agmatine. Experimental, Investigational Agomelatine The risk or severity of adverse effects can be increased when Protriptyline is combined with Agomelatine. Approved, Investigational Alaproclate The risk or severity of adverse effects can be increased when Protriptyline is combined with Alaproclate. Experimental Alfaxalone The risk or severity of adverse effects can be increased when Protriptyline is combined with Alfaxalone. Vet Approved Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Protriptyline. Approved, Illicit Allopregnanolone The risk or severity of adverse effects can be increased when Protriptyline is combined with Allopregnanolone. Investigational Almotriptan The risk or severity of adverse effects can be increased when Protriptyline is combined with Almotriptan. Approved, Investigational Alogliptin The serum concentration of Protriptyline can be increased when it is combined with Alogliptin. Approved Alosetron Alosetron may increase the serotonergic activities of Protriptyline. Approved, Withdrawn Alpha-1-proteinase inhibitor The serum concentration of Protriptyline can be increased when it is combined with Alpha-1-proteinase inhibitor. Approved Alphacetylmethadol The risk or severity of adverse effects can be increased when Protriptyline is combined with Alphacetylmethadol. Experimental, Illicit Alphaprodine The risk or severity of adverse effects can be increased when Protriptyline is combined with Alphaprodine. Illicit Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Protriptyline. Approved, Illicit, Investigational Altretamine Altretamine may increase the orthostatic hypotensive activities of Protriptyline. Approved Amiodarone The metabolism of Protriptyline can be decreased when combined with Amiodarone. Approved, Investigational Amisulpride The risk or severity of adverse effects can be increased when Protriptyline is combined with Amisulpride. Approved, Investigational Amitraz Protriptyline may decrease the antihypertensive activities of Amitraz. Vet Approved Amitriptyline The risk or severity of adverse effects can be increased when Amitriptyline is combined with Protriptyline. Approved Amobarbital The metabolism of Protriptyline can be increased when combined with Amobarbital. Approved, Illicit Amoxapine The risk or severity of adverse effects can be increased when Protriptyline is combined with Amoxapine. Approved Amperozide The risk or severity of adverse effects can be increased when Protriptyline is combined with Amperozide. Experimental Amphetamine Amphetamine may increase the serotonergic activities of Protriptyline. Approved, Illicit, Investigational Amprenavir The serum concentration of Protriptyline can be increased when it is combined with Amprenavir. Approved, Investigational Anagrelide Protriptyline may increase the QTc-prolonging activities of Anagrelide. Approved Antithrombin III human The serum concentration of Protriptyline can be increased when it is combined with Antithrombin III human. Approved Apixaban The serum concentration of Protriptyline can be increased when it is combined with Apixaban. Approved Apomorphine Protriptyline may decrease the antihypertensive activities of Apomorphine. Approved, Investigational Apraclonidine Protriptyline may decrease the antihypertensive activities of Apraclonidine. Approved Aprotinin The serum concentration of Protriptyline can be increased when it is combined with Aprotinin. Approved, Investigational, Withdrawn Arbutamine The risk or severity of adverse effects can be increased when Protriptyline is combined with Arbutamine. Approved Arformoterol The risk or severity of adverse effects can be increased when Protriptyline is combined with Arformoterol. Approved, Investigational Argatroban The serum concentration of Protriptyline can be increased when it is combined with Argatroban. Approved, Investigational Aripiprazole The risk or severity of adverse effects can be increased when Aripiprazole is combined with Protriptyline. Approved, Investigational Arsenic trioxide Protriptyline may increase the QTc-prolonging activities of Arsenic trioxide. Approved, Investigational Artemether Protriptyline may increase the QTc-prolonging activities of Artemether. Approved Articaine The risk or severity of adverse effects can be increased when Protriptyline is combined with Articaine. Approved Asenapine Protriptyline may increase the QTc-prolonging activities of Asenapine. Approved Asunaprevir The serum concentration of Protriptyline can be increased when it is combined with Asunaprevir. Approved, Investigational, Withdrawn Atazanavir The serum concentration of Protriptyline can be increased when it is combined with Atazanavir. Approved, Investigational Atomoxetine The metabolism of Protriptyline can be decreased when combined with Atomoxetine. Approved Azaperone The risk or severity of adverse effects can be increased when Protriptyline is combined with Azaperone. Investigational, Vet Approved Azelastine Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Azelastine. Approved Azithromycin Protriptyline may increase the QTc-prolonging activities of Azithromycin. Approved Baclofen The risk or severity of adverse effects can be increased when Baclofen is combined with Protriptyline. Approved Bambuterol The risk or severity of adverse effects can be increased when Protriptyline is combined with Bambuterol. Approved, Investigational Barbexaclone The metabolism of Protriptyline can be increased when combined with Barbexaclone. Experimental Barbital The metabolism of Protriptyline can be increased when combined with Barbital. Illicit Batimastat The serum concentration of Protriptyline can be increased when it is combined with Batimastat. Experimental Bedaquiline Protriptyline may increase the QTc-prolonging activities of Bedaquiline. Approved Benazepril The serum concentration of Protriptyline can be increased when it is combined with Benazepril. Approved, Investigational Benmoxin Benmoxin may increase the serotonergic activities of Protriptyline. Withdrawn Benperidol The risk or severity of adverse effects can be increased when Protriptyline is combined with Benperidol. Approved, Investigational Benzamidine The serum concentration of Protriptyline can be increased when it is combined with Benzamidine. Experimental Benzocaine The risk or severity of adverse effects can be increased when Protriptyline is combined with Benzocaine. Approved, Investigational Benzphetamine Protriptyline may decrease the antihypertensive activities of Benzphetamine. Approved, Illicit Benzyl alcohol The risk or severity of adverse effects can be increased when Protriptyline is combined with Benzyl alcohol. Approved Betaxolol The metabolism of Protriptyline can be decreased when combined with Betaxolol. Approved, Investigational Bethanidine Protriptyline may decrease the antihypertensive activities of Bethanidine. Approved Bifeprunox The risk or severity of adverse effects can be increased when Protriptyline is combined with Bifeprunox. Investigational Bitolterol The risk or severity of adverse effects can be increased when Protriptyline is combined with Bitolterol. Withdrawn Bivalirudin The serum concentration of Protriptyline can be increased when it is combined with Bivalirudin. Approved, Investigational Boceprevir The serum concentration of Protriptyline can be increased when it is combined with Boceprevir. Approved, Withdrawn Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Protriptyline. Approved Brentuximab vedotin The serum concentration of Brentuximab vedotin can be increased when it is combined with Protriptyline. Approved, Investigational Brexpiprazole The risk or severity of adverse effects can be increased when Protriptyline is combined with Brexpiprazole. Approved, Investigational Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Protriptyline. Approved Brofaromine Brofaromine may increase the serotonergic activities of Protriptyline. Experimental Bromazepam The risk or severity of adverse effects can be increased when Bromazepam is combined with Protriptyline. Approved, Illicit, Investigational Bromisoval The risk or severity of adverse effects can be increased when Protriptyline is combined with Bromisoval. Experimental Bromocriptine Protriptyline may decrease the antihypertensive activities of Bromocriptine. Approved, Investigational Bromperidol The risk or severity of adverse effects can be increased when Protriptyline is combined with Bromperidol. Approved, Investigational Brompheniramine The risk or severity of adverse effects can be increased when Protriptyline is combined with Brompheniramine. Approved Brotizolam The risk or severity of adverse effects can be increased when Protriptyline is combined with Brotizolam. Approved, Investigational, Withdrawn Bupivacaine The risk or severity of adverse effects can be increased when Protriptyline is combined with Bupivacaine. Approved, Investigational Buprenorphine Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Approved, Illicit, Investigational, Vet Approved Bupropion The metabolism of Protriptyline can be decreased when combined with Bupropion. Approved Buspirone The risk or severity of adverse effects can be increased when Protriptyline is combined with Buspirone. Approved, Investigational Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Protriptyline. Approved, Illicit Butacaine The risk or severity of adverse effects can be increased when Protriptyline is combined with Butacaine. Vet Approved Butalbital The risk or severity of adverse effects can be increased when Butalbital is combined with Protriptyline. Approved, Illicit Butamben The risk or severity of adverse effects can be increased when Protriptyline is combined with Butamben. Approved, Withdrawn Butaperazine The risk or severity of adverse effects can be increased when Protriptyline is combined with Butaperazine. Experimental Butethal The risk or severity of adverse effects can be increased when Protriptyline is combined with Butethal. Approved, Illicit Butorphanol The risk or severity of adverse effects can be increased when Butorphanol is combined with Protriptyline. Approved, Illicit, Vet Approved Cabergoline The risk or severity of adverse effects can be increased when Cabergoline is combined with Protriptyline. Approved Camostat The serum concentration of Protriptyline can be increased when it is combined with Camostat. Experimental Candoxatril The serum concentration of Protriptyline can be increased when it is combined with Candoxatril. Experimental Candoxatrilat The serum concentration of Protriptyline can be increased when it is combined with Candoxatrilat. Experimental Canertinib The risk or severity of adverse effects can be increased when Protriptyline is combined with Canertinib. Investigational Captopril The serum concentration of Protriptyline can be increased when it is combined with Captopril. Approved Carbamazepine The metabolism of Protriptyline can be increased when combined with Carbamazepine. Approved, Investigational Carbinoxamine The risk or severity of adverse effects can be increased when Protriptyline is combined with Carbinoxamine. Approved Carfentanil The risk or severity of adverse effects can be increased when Protriptyline is combined with Carfentanil. Illicit, Investigational, Vet Approved Cariprazine The risk or severity of adverse effects can be increased when Protriptyline is combined with Cariprazine. Approved, Investigational Carisoprodol The risk or severity of adverse effects can be increased when Protriptyline is combined with Carisoprodol. Approved Caroxazone Caroxazone may increase the serotonergic activities of Protriptyline. Withdrawn Celecoxib The metabolism of Protriptyline can be decreased when combined with Celecoxib. Approved, Investigational Celiprolol The risk or severity of adverse effects can be increased when Protriptyline is combined with Celiprolol. Approved, Investigational Ceritinib Protriptyline may increase the QTc-prolonging activities of Ceritinib. Approved Cetirizine The risk or severity of adverse effects can be increased when Cetirizine is combined with Protriptyline. Approved Chloral hydrate The risk or severity of adverse effects can be increased when Protriptyline is combined with Chloral hydrate. Approved, Illicit, Investigational, Vet Approved Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Protriptyline. Approved, Illicit, Investigational Chlormezanone The risk or severity of adverse effects can be increased when Protriptyline is combined with Chlormezanone. Approved, Investigational, Withdrawn Chloroprocaine The risk or severity of adverse effects can be increased when Protriptyline is combined with Chloroprocaine. Approved Chloroquine The metabolism of Protriptyline can be decreased when combined with Chloroquine. Approved, Investigational, Vet Approved Chlorphenamine The risk or severity of adverse effects can be increased when Protriptyline is combined with Chlorphenamine. Approved Chlorphentermine Protriptyline may increase the stimulatory activities of Chlorphentermine. Illicit, Withdrawn Chlorproethazine The risk or severity of adverse effects can be increased when Protriptyline is combined with Chlorproethazine. Experimental Chlorpromazine The metabolism of Protriptyline can be decreased when combined with Chlorpromazine. Approved, Investigational, Vet Approved Chlorprothixene The risk or severity of adverse effects can be increased when Protriptyline is combined with Chlorprothixene. Approved, Investigational, Withdrawn Chlorzoxazone The risk or severity of adverse effects can be increased when Protriptyline is combined with Chlorzoxazone. Approved Cholecalciferol The metabolism of Protriptyline can be decreased when combined with Cholecalciferol. Approved, Nutraceutical Chymostatin The serum concentration of Protriptyline can be increased when it is combined with Chymostatin. Experimental Cilastatin The serum concentration of Protriptyline can be increased when it is combined with Cilastatin. Approved, Investigational Cilazapril The serum concentration of Protriptyline can be increased when it is combined with Cilazapril. Approved Cimetidine The metabolism of Protriptyline can be decreased when combined with Cimetidine. Approved, Investigational Cinacalcet The serum concentration of Protriptyline can be increased when it is combined with Cinacalcet. Approved Cinchocaine The risk or severity of adverse effects can be increased when Protriptyline is combined with Cinchocaine. Approved, Vet Approved Ciprofloxacin Protriptyline may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational Cirazoline Protriptyline may increase the vasopressor activities of Cirazoline. Experimental Cisapride Protriptyline may increase the arrhythmogenic activities of Cisapride. Approved, Investigational, Withdrawn Citalopram The risk or severity of adverse effects can be increased when Protriptyline is combined with Citalopram. Approved Clarithromycin Protriptyline may increase the QTc-prolonging activities of Clarithromycin. Approved Clemastine The metabolism of Protriptyline can be decreased when combined with Clemastine. Approved, Investigational Clenbuterol The risk or severity of adverse effects can be increased when Protriptyline is combined with Clenbuterol. Approved, Investigational, Vet Approved Clidinium The risk or severity of adverse effects can be increased when Protriptyline is combined with Clidinium. Approved Clobazam The metabolism of Protriptyline can be decreased when combined with Clobazam. Approved, Illicit clomethiazole The risk or severity of adverse effects can be increased when Protriptyline is combined with clomethiazole. Investigational Clomipramine The risk or severity of adverse effects can be increased when Protriptyline is combined with Clomipramine. Approved, Investigational, Vet Approved Clonazepam The risk or severity of adverse effects can be increased when Protriptyline is combined with Clonazepam. Approved, Illicit Clonidine Protriptyline may decrease the antihypertensive activities of Clonidine. Approved Clopenthixol The risk or severity of adverse effects can be increased when Protriptyline is combined with Clopenthixol. Experimental Clorazepate The risk or severity of adverse effects can be increased when Clorazepate is combined with Protriptyline. Approved, Illicit Clorindione Protriptyline may increase the anticoagulant activities of Clorindione. Experimental Clothiapine The risk or severity of adverse effects can be increased when Protriptyline is combined with Clothiapine. Experimental Clotrimazole The metabolism of Protriptyline can be decreased when combined with Clotrimazole. Approved, Vet Approved Clozapine The metabolism of Protriptyline can be decreased when combined with Clozapine. Approved Cobicistat The serum concentration of Protriptyline can be increased when it is combined with Cobicistat. Approved Cocaine The metabolism of Protriptyline can be decreased when combined with Cocaine. Approved, Illicit Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Protriptyline. Approved, Illicit Colchicine The serum concentration of Colchicine can be increased when it is combined with Protriptyline. Approved Crizotinib Protriptyline may increase the QTc-prolonging activities of Crizotinib. Approved Curcumin The metabolism of Protriptyline can be decreased when combined with Curcumin. Approved, Investigational Cyamemazine The risk or severity of adverse effects can be increased when Protriptyline is combined with Cyamemazine. Approved Cyclizine The risk or severity of adverse effects can be increased when Protriptyline is combined with Cyclizine. Approved Cyclobenzaprine The risk or severity of adverse effects can be increased when Protriptyline is combined with Cyclobenzaprine. Approved Cyclopropane The risk or severity of adverse effects can be increased when Protriptyline is combined with Cyclopropane. Experimental Cyproheptadine The risk or severity of adverse effects can be increased when Protriptyline is combined with Cyproheptadine. Approved Dabigatran etexilate The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Protriptyline. Approved Dantrolene The risk or severity of adverse effects can be increased when Protriptyline is combined with Dantrolene. Approved, Investigational Dapiprazole The risk or severity of adverse effects can be increased when Protriptyline is combined with Dapiprazole. Approved Dapoxetine The risk or severity of adverse effects can be increased when Dapoxetine is combined with Protriptyline. Investigational Darexaban The serum concentration of Protriptyline can be increased when it is combined with Darexaban. Investigational Darifenacin The metabolism of Protriptyline can be decreased when combined with Darifenacin. Approved, Investigational Darunavir The serum concentration of Protriptyline can be increased when it is combined with Darunavir. Approved Delanzomib The serum concentration of Protriptyline can be increased when it is combined with Delanzomib. Investigational Delapril The serum concentration of Protriptyline can be increased when it is combined with Delapril. Investigational Delavirdine The metabolism of Protriptyline can be decreased when combined with Delavirdine. Approved Deramciclane The risk or severity of adverse effects can be increased when Protriptyline is combined with Deramciclane. Investigational Desflurane The risk or severity of adverse effects can be increased when Desflurane is combined with Protriptyline. Approved Desipramine The risk or severity of adverse effects can be increased when Protriptyline is combined with Desipramine. Approved, Investigational Desloratadine The risk or severity of adverse effects can be increased when Protriptyline is combined with Desloratadine. Approved, Investigational Desmopressin The risk or severity of adverse effects can be increased when Protriptyline is combined with Desmopressin. Approved Desvenlafaxine The risk or severity of adverse effects can be increased when Protriptyline is combined with Desvenlafaxine. Approved, Investigational Detomidine Protriptyline may decrease the antihypertensive activities of Detomidine. Vet Approved Dexbrompheniramine The risk or severity of adverse effects can be increased when Protriptyline is combined with Dexbrompheniramine. Approved Dexmedetomidine Protriptyline may decrease the antihypertensive activities of Dexmedetomidine. Approved, Vet Approved Dexmethylphenidate The risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Protriptyline. Approved, Investigational Dextroamphetamine Protriptyline may increase the stimulatory activities of Dextroamphetamine. Approved, Illicit Dextromethorphan The risk or severity of adverse effects can be increased when Protriptyline is combined with Dextromethorphan. Approved Dextromoramide The risk or severity of adverse effects can be increased when Protriptyline is combined with Dextromoramide. Experimental, Illicit Dextropropoxyphene The risk or severity of adverse effects can be increased when Protriptyline is combined with Dextropropoxyphene. Approved, Illicit, Investigational, Withdrawn Dezocine The risk or severity of adverse effects can be increased when Protriptyline is combined with Dezocine. Approved, Investigational Diazepam The risk or severity of adverse effects can be increased when Diazepam is combined with Protriptyline. Approved, Illicit, Investigational, Vet Approved Dicoumarol Protriptyline may increase the anticoagulant activities of Dicoumarol. Approved Diethyl ether The risk or severity of adverse effects can be increased when Protriptyline is combined with Diethyl ether. Experimental Diethylpropion Protriptyline may increase the stimulatory activities of Diethylpropion. Approved, Illicit Difenoxin The risk or severity of adverse effects can be increased when Protriptyline is combined with Difenoxin. Approved, Illicit Dihydrocodeine The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Protriptyline. Approved, Illicit Dihydroergotamine Protriptyline may decrease the antihypertensive activities of Dihydroergotamine. Approved, Investigational Dihydroetorphine The risk or severity of adverse effects can be increased when Protriptyline is combined with Dihydroetorphine. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Protriptyline is combined with Dihydromorphine. Experimental, Illicit Dimenhydrinate The risk or severity of adverse effects can be increased when Protriptyline is combined with Dimenhydrinate. Approved Diphenadione Protriptyline may increase the anticoagulant activities of Diphenadione. Experimental Diphenhydramine The metabolism of Protriptyline can be decreased when combined with Diphenhydramine. Approved, Investigational Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Protriptyline. Approved, Illicit Dipivefrin Protriptyline may decrease the antihypertensive activities of Dipivefrin. Approved Disopyramide Protriptyline may increase the QTc-prolonging activities of Disopyramide. Approved Dixyrazine The risk or severity of adverse effects can be increased when Protriptyline is combined with Dixyrazine. Experimental DL-Methylephedrine Protriptyline may decrease the antihypertensive activities of DL-Methylephedrine. Approved Dobutamine The risk or severity of adverse effects can be increased when Protriptyline is combined with Dobutamine. Approved Dofetilide Protriptyline may increase the QTc-prolonging activities of Dofetilide. Approved, Investigational Dolasetron Protriptyline may increase the QTc-prolonging activities of Dolasetron. Approved, Investigational Domperidone Protriptyline may increase the QTc-prolonging activities of Domperidone. Approved, Investigational, Vet Approved Doramectin The risk or severity of adverse effects can be increased when Protriptyline is combined with Doramectin. Vet Approved Dosulepin The metabolism of Protriptyline can be decreased when combined with Dosulepin. Approved Doxepin The risk or severity of adverse effects can be increased when Protriptyline is combined with Doxepin. Approved, Investigational Doxofylline The risk or severity of adverse effects can be increased when Protriptyline is combined with Doxofylline. Approved, Investigational Doxorubicin The serum concentration of Doxorubicin can be increased when it is combined with Protriptyline. Approved, Investigational Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Protriptyline. Approved, Vet Approved DPDPE The risk or severity of adverse effects can be increased when Protriptyline is combined with DPDPE. Experimental Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Protriptyline. Approved, Illicit Dronedarone Protriptyline may increase the QTc-prolonging activities of Dronedarone. Approved Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Protriptyline. Approved, Vet Approved Drotebanol The risk or severity of adverse effects can be increased when Protriptyline is combined with Drotebanol. Experimental, Illicit Droxidopa Protriptyline may decrease the antihypertensive activities of Droxidopa. Approved, Investigational Duloxetine Duloxetine may increase the serotonergic activities of Protriptyline. Approved Dyclonine The risk or severity of adverse effects can be increased when Protriptyline is combined with Dyclonine. Approved Ecabet The serum concentration of Protriptyline can be increased when it is combined with Ecabet. Approved, Investigational Ecgonine The risk or severity of adverse effects can be increased when Protriptyline is combined with Ecgonine. Experimental, Illicit Ecopipam The risk or severity of adverse effects can be increased when Protriptyline is combined with Ecopipam. Investigational Edoxaban The serum concentration of Edoxaban can be increased when it is combined with Protriptyline. Approved Efavirenz The risk or severity of adverse effects can be increased when Protriptyline is combined with Efavirenz. Approved, Investigational Elafin The serum concentration of Protriptyline can be increased when it is combined with Elafin. Investigational Eletriptan The risk or severity of adverse effects can be increased when Eletriptan is combined with Protriptyline. Approved, Investigational Eliglustat Protriptyline may increase the QTc-prolonging activities of Eliglustat. Approved Eltanolone The risk or severity of adverse effects can be increased when Protriptyline is combined with Eltanolone. Investigational Enalapril The serum concentration of Protriptyline can be increased when it is combined with Enalapril. Approved, Vet Approved Enalaprilat The serum concentration of Protriptyline can be increased when it is combined with Enalaprilat. Approved Enalkiren The serum concentration of Protriptyline can be increased when it is combined with Enalkiren. Experimental Enflurane The risk or severity of adverse effects can be increased when Protriptyline is combined with Enflurane. Approved, Investigational, Vet Approved Entacapone The risk or severity of adverse effects can be increased when Protriptyline is combined with Entacapone. Approved, Investigational Ephedra Protriptyline may decrease the antihypertensive activities of Ephedra. Approved, Nutraceutical, Withdrawn Epinephrine Protriptyline may decrease the antihypertensive activities of Epinephrine. Approved, Vet Approved Ergoloid mesylate The risk or severity of adverse effects can be increased when Protriptyline is combined with Ergoloid mesylate. Approved Ergonovine The risk or severity of adverse effects can be increased when Protriptyline is combined with Ergonovine. Approved Ergotamine Protriptyline may decrease the antihypertensive activities of Ergotamine. Approved Erythromycin Protriptyline may increase the QTc-prolonging activities of Erythromycin. Approved, Investigational, Vet Approved Escitalopram The risk or severity of adverse effects can be increased when Protriptyline is combined with Escitalopram. Approved, Investigational Estazolam The risk or severity of adverse effects can be increased when Estazolam is combined with Protriptyline. Approved, Illicit Eszopiclone The risk or severity of adverse effects can be increased when Eszopiclone is combined with Protriptyline. Approved, Investigational Etafedrine The risk or severity of adverse effects can be increased when Protriptyline is combined with Etafedrine. Approved Ethanol Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Ethanol. Approved Ethchlorvynol The risk or severity of adverse effects can be increased when Protriptyline is combined with Ethchlorvynol. Approved, Illicit, Withdrawn Ethosuximide The risk or severity of adverse effects can be increased when Protriptyline is combined with Ethosuximide. Approved Ethotoin The risk or severity of adverse effects can be increased when Protriptyline is combined with Ethotoin. Approved Ethyl biscoumacetate Protriptyline may increase the anticoagulant activities of Ethyl biscoumacetate. Withdrawn Ethyl carbamate The risk or severity of adverse effects can be increased when Protriptyline is combined with Ethyl carbamate. Withdrawn Ethyl chloride The risk or severity of adverse effects can be increased when Protriptyline is combined with Ethyl chloride. Approved, Experimental, Investigational Ethyl loflazepate The risk or severity of adverse effects can be increased when Protriptyline is combined with Ethyl loflazepate. Approved, Illicit Ethylmorphine The risk or severity of adverse effects can be increased when Protriptyline is combined with Ethylmorphine. Approved, Illicit Etidocaine The risk or severity of adverse effects can be increased when Protriptyline is combined with Etidocaine. Approved Etifoxine The risk or severity of adverse effects can be increased when Protriptyline is combined with Etifoxine. Investigational, Withdrawn Etizolam The risk or severity of adverse effects can be increased when Protriptyline is combined with Etizolam. Approved Etomidate Protriptyline may decrease the antihypertensive activities of Etomidate. Approved Etoperidone The risk or severity of adverse effects can be increased when Protriptyline is combined with Etoperidone. Withdrawn Etorphine The risk or severity of adverse effects can be increased when Protriptyline is combined with Etorphine. Illicit, Vet Approved Everolimus The serum concentration of Everolimus can be increased when it is combined with Protriptyline. Approved Ezogabine The risk or severity of adverse effects can be increased when Protriptyline is combined with Ezogabine. Approved, Investigational Faldaprevir The serum concentration of Protriptyline can be increased when it is combined with Faldaprevir. Investigational Felbamate The risk or severity of adverse effects can be increased when Protriptyline is combined with Felbamate. Approved Fencamfamine The risk or severity of adverse effects can be increased when Protriptyline is combined with Fencamfamine. Approved, Illicit, Withdrawn Fenoterol The risk or severity of adverse effects can be increased when Protriptyline is combined with Fenoterol. Approved, Investigational Fentanyl The risk or severity of adverse effects can be increased when Protriptyline is combined with Fentanyl. Approved, Illicit, Investigational, Vet Approved Fexofenadine The risk or severity of adverse effects can be increased when Protriptyline is combined with Fexofenadine. Approved, Investigational Flecainide Protriptyline may increase the QTc-prolonging activities of Flecainide. Approved, Withdrawn Flibanserin The risk or severity of adverse effects can be increased when Protriptyline is combined with Flibanserin. Approved, Investigational Fluanisone The risk or severity of adverse effects can be increased when Protriptyline is combined with Fluanisone. Experimental Fludiazepam The risk or severity of adverse effects can be increased when Protriptyline is combined with Fludiazepam. Approved, Illicit Fluindione Protriptyline may increase the anticoagulant activities of Fluindione. Approved, Investigational Flunarizine The risk or severity of adverse effects can be increased when Protriptyline is combined with Flunarizine. Approved Flunitrazepam The risk or severity of adverse effects can be increased when Protriptyline is combined with Flunitrazepam. Approved, Illicit Fluoxetine The risk or severity of adverse effects can be increased when Fluoxetine is combined with Protriptyline. Approved, Vet Approved Flupentixol Protriptyline may increase the QTc-prolonging activities of Flupentixol. Approved, Investigational, Withdrawn Fluphenazine The risk or severity of adverse effects can be increased when Fluphenazine is combined with Protriptyline. Approved Flurazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Protriptyline. Approved, Illicit, Investigational Fluspirilene The risk or severity of adverse effects can be increased when Protriptyline is combined with Fluspirilene. Approved, Investigational Fluticasone propionate The risk or severity of adverse effects can be increased when Protriptyline is combined with Fluticasone propionate. Approved Fluvoxamine The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Protriptyline. Approved, Investigational Formoterol The risk or severity of adverse effects can be increased when Protriptyline is combined with Formoterol. Approved, Investigational Fosamprenavir The serum concentration of Protriptyline can be increased when it is combined with Fosamprenavir. Approved Fosinopril The serum concentration of Protriptyline can be increased when it is combined with Fosinopril. Approved Fosphenytoin The risk or severity of adverse effects can be increased when Protriptyline is combined with Fosphenytoin. Approved, Investigational Fospropofol The risk or severity of adverse effects can be increased when Protriptyline is combined with Fospropofol. Approved, Illicit, Investigational Frovatriptan The risk or severity of adverse effects can be increased when Protriptyline is combined with Frovatriptan. Approved, Investigational Furazolidone Furazolidone may increase the serotonergic activities of Protriptyline. Approved, Investigational, Vet Approved Gabapentin The risk or severity of adverse effects can be increased when Gabapentin is combined with Protriptyline. Approved, Investigational Gabapentin Enacarbil The risk or severity of adverse effects can be increased when Protriptyline is combined with Gabapentin Enacarbil. Approved, Investigational Gabexate The serum concentration of Protriptyline can be increased when it is combined with Gabexate. Investigational Gadobenic acid Protriptyline may increase the QTc-prolonging activities of Gadobenic acid. Approved, Investigational Gamma Hydroxybutyric Acid The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Protriptyline. Approved, Illicit, Investigational Geldanamycin The serum concentration of Protriptyline can be increased when it is combined with Geldanamycin. Experimental, Investigational Gemifloxacin Protriptyline may increase the QTc-prolonging activities of Gemifloxacin. Approved, Investigational Gepefrine Protriptyline may increase the stimulatory activities of Gepefrine. Experimental Gepirone The risk or severity of adverse effects can be increased when Protriptyline is combined with Gepirone. Investigational Glutethimide The risk or severity of adverse effects can be increased when Protriptyline is combined with Glutethimide. Approved, Illicit GM6001 The serum concentration of Protriptyline can be increased when it is combined with GM6001. Experimental Goserelin Protriptyline may increase the QTc-prolonging activities of Goserelin. Approved Granisetron Protriptyline may increase the QTc-prolonging activities of Granisetron. Approved, Investigational Guanabenz Protriptyline may decrease the antihypertensive activities of Guanabenz. Approved, Investigational Guanfacine Protriptyline may decrease the antihypertensive activities of Guanfacine. Approved, Investigational Halazepam The risk or severity of adverse effects can be increased when Protriptyline is combined with Halazepam. Approved, Illicit, Withdrawn Haloperidol The metabolism of Protriptyline can be decreased when combined with Haloperidol. Approved Halothane The risk or severity of adverse effects can be increased when Protriptyline is combined with Halothane. Approved, Vet Approved Harmaline Harmaline may increase the serotonergic activities of Protriptyline. Experimental Heroin The risk or severity of adverse effects can be increased when Protriptyline is combined with Heroin. Approved, Illicit, Investigational Hexobarbital The metabolism of Protriptyline can be increased when combined with Hexobarbital. Approved Hexoprenaline The risk or severity of adverse effects can be increased when Protriptyline is combined with Hexoprenaline. Approved, Withdrawn Hydracarbazine Hydracarbazine may increase the serotonergic activities of Protriptyline. Experimental Hydrocodone Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. Approved, Illicit Hydromorphone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Protriptyline. Approved, Illicit Hydroxyamphetamine Protriptyline may increase the stimulatory activities of Hydroxyamphetamine. Approved Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Protriptyline. Approved Ibutilide Protriptyline may increase the QTc-prolonging activities of Ibutilide. Approved Idraparinux The serum concentration of Protriptyline can be increased when it is combined with Idraparinux. Investigational Iloperidone Protriptyline may increase the QTc-prolonging activities of Iloperidone. Approved Imidapril The serum concentration of Protriptyline can be increased when it is combined with Imidapril. Investigational Imipramine The risk or severity of adverse effects can be increased when Protriptyline is combined with Imipramine. Approved Indacaterol The risk or severity of adverse effects can be increased when Protriptyline is combined with Indacaterol. Approved Indalpine The risk or severity of adverse effects can be increased when Protriptyline is combined with Indalpine. Investigational, Withdrawn Indinavir The serum concentration of Protriptyline can be increased when it is combined with Indinavir. Approved Indiplon The risk or severity of adverse effects can be increased when Protriptyline is combined with Indiplon. Investigational Iobenguane The therapeutic efficacy of Iobenguane can be decreased when used in combination with Protriptyline. Approved, Investigational Iofetamine I-123 Protriptyline may increase the stimulatory activities of Iofetamine I-123. Approved Iproclozide Iproclozide may increase the serotonergic activities of Protriptyline. Withdrawn Iproniazid Iproniazid may increase the serotonergic activities of Protriptyline. Withdrawn Isocarboxazid The therapeutic efficacy of Protriptyline can be increased when used in combination with Isocarboxazid. Approved Isoetarine The risk or severity of adverse effects can be increased when Protriptyline is combined with Isoetarine. Approved Isoflurane The risk or severity of adverse effects can be increased when Isoflurane is combined with Protriptyline. Approved, Vet Approved Isoflurophate The serum concentration of Protriptyline can be increased when it is combined with Isoflurophate. Approved, Investigational, Withdrawn Isometheptene Protriptyline may increase the vasopressor activities of Isometheptene. Approved Isoniazid The metabolism of Protriptyline can be decreased when combined with Isoniazid. Approved, Investigational Isoprenaline The risk or severity of adverse effects can be increased when Protriptyline is combined with Isoprenaline. Approved, Investigational Ixazomib The serum concentration of Protriptyline can be increased when it is combined with Ixazomib. Approved, Investigational Ketamine The risk or severity of adverse effects can be increased when Ketamine is combined with Protriptyline. Approved, Vet Approved Ketazolam The risk or severity of adverse effects can be increased when Protriptyline is combined with Ketazolam. Approved Ketobemidone The risk or severity of adverse effects can be increased when Protriptyline is combined with Ketobemidone. Approved, Investigational Ketoconazole The metabolism of Protriptyline can be decreased when combined with Ketoconazole. Approved, Investigational L-Tryptophan L-Tryptophan may increase the serotonergic activities of Protriptyline. Approved, Nutraceutical, Withdrawn Lamotrigine The risk or severity of adverse effects can be increased when Protriptyline is combined with Lamotrigine. Approved, Investigational Ledipasvir The serum concentration of Ledipasvir can be increased when it is combined with Protriptyline. Approved Lenvatinib Protriptyline may increase the QTc-prolonging activities of Lenvatinib. Approved, Investigational Lepirudin The serum concentration of Protriptyline can be increased when it is combined with Lepirudin. Approved Letaxaban The serum concentration of Protriptyline can be increased when it is combined with Letaxaban. Investigational Leuprolide Protriptyline may increase the QTc-prolonging activities of Leuprolide. Approved, Investigational Levetiracetam The risk or severity of adverse effects can be increased when Protriptyline is combined with Levetiracetam. Approved, Investigational Levobupivacaine The risk or severity of adverse effects can be increased when Protriptyline is combined with Levobupivacaine. Approved, Investigational Levocabastine The risk or severity of adverse effects can be increased when Protriptyline is combined with Levocabastine. Approved, Investigational Levocetirizine The risk or severity of adverse effects can be increased when Protriptyline is combined with Levocetirizine. Approved Levodopa The risk or severity of adverse effects can be increased when Protriptyline is combined with Levodopa. Approved Levofloxacin Protriptyline may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Levomethadyl Acetate The risk or severity of adverse effects can be increased when Protriptyline is combined with Levomethadyl Acetate. Approved, Investigational Levomilnacipran The risk or severity of adverse effects can be increased when Protriptyline is combined with Levomilnacipran. Approved, Investigational Levonordefrin Protriptyline may decrease the antihypertensive activities of Levonordefrin. Approved Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Protriptyline. Approved Levosalbutamol The risk or severity of adverse effects can be increased when Protriptyline is combined with Levosalbutamol. Approved, Investigational Levothyroxine Levothyroxine may increase the arrhythmogenic activities of Protriptyline. Approved Lidocaine The risk or severity of adverse effects can be increased when Protriptyline is combined with Lidocaine. Approved, Vet Approved Linagliptin The serum concentration of Protriptyline can be increased when it is combined with Linagliptin. Approved Linezolid Linezolid may increase the serotonergic activities of Protriptyline. Approved, Investigational Liothyronine Liothyronine may increase the arrhythmogenic activities of Protriptyline. Approved, Vet Approved Liotrix Liotrix may increase the arrhythmogenic activities of Protriptyline. Approved Lisdexamfetamine Protriptyline may increase the stimulatory activities of Lisdexamfetamine. Approved, Investigational Lisinopril The serum concentration of Protriptyline can be increased when it is combined with Lisinopril. Approved, Investigational Lithium cation Lithium may increase the neurotoxic activities of Protriptyline. Experimental Lofentanil The risk or severity of adverse effects can be increased when Protriptyline is combined with Lofentanil. Illicit Lofexidine The therapeutic efficacy of Protriptyline can be increased when used in combination with Lofexidine. Approved, Investigational Lopinavir The metabolism of Protriptyline can be decreased when combined with Lopinavir. Approved Loprazolam The risk or severity of adverse effects can be increased when Protriptyline is combined with Loprazolam. Experimental Loratadine The risk or severity of adverse effects can be increased when Protriptyline is combined with Loratadine. Approved, Investigational Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Protriptyline. Approved Lorcaserin The risk or severity of adverse effects can be increased when Protriptyline is combined with Lorcaserin. Approved Lormetazepam The risk or severity of adverse effects can be increased when Protriptyline is combined with Lormetazepam. Approved Lorpiprazole The serum concentration of Protriptyline can be increased when it is combined with Lorpiprazole. Approved Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Protriptyline. Approved Lumefantrine Protriptyline may increase the QTc-prolonging activities of Lumefantrine. Approved Lurasidone The risk or severity of adverse effects can be increased when Lurasidone is combined with Protriptyline. Approved, Investigational Magnesium sulfate The therapeutic efficacy of Protriptyline can be increased when used in combination with Magnesium sulfate. Approved, Investigational, Vet Approved Manidipine The metabolism of Protriptyline can be decreased when combined with Manidipine. Approved, Investigational Maprotiline The risk or severity of adverse effects can be increased when Protriptyline is combined with Maprotiline. Approved, Investigational Mebanazine Mebanazine may increase the serotonergic activities of Protriptyline. Withdrawn Mebicar The risk or severity of adverse effects can be increased when Protriptyline is combined with Mebicar. Experimental Meclizine The risk or severity of adverse effects can be increased when Protriptyline is combined with Meclizine. Approved Medazepam The risk or severity of adverse effects can be increased when Protriptyline is combined with Medazepam. Experimental Medetomidine Protriptyline may decrease the antihypertensive activities of Medetomidine. Vet Approved Melagatran The serum concentration of Protriptyline can be increased when it is combined with Melagatran. Experimental Melatonin The risk or severity of adverse effects can be increased when Protriptyline is combined with Melatonin. Approved, Nutraceutical, Vet Approved Melperone The risk or severity of adverse effects can be increased when Protriptyline is combined with Melperone. Approved, Investigational Mephedrone Protriptyline may increase the stimulatory activities of Mephedrone. Investigational Mephentermine Protriptyline may increase the vasopressor activities of Mephentermine. Approved Mepivacaine The risk or severity of adverse effects can be increased when Protriptyline is combined with Mepivacaine. Approved, Vet Approved Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Protriptyline. Approved, Illicit Meptazinol The risk or severity of adverse effects can be increased when Protriptyline is combined with Meptazinol. Experimental Mesoridazine The risk or severity of adverse effects can be increased when Protriptyline is combined with Mesoridazine. Approved, Investigational Metaraminol Protriptyline may increase the vasopressor activities of Metaraminol. Approved, Investigational Metaxalone The risk or severity of adverse effects can be increased when Protriptyline is combined with Metaxalone. Approved Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Protriptyline. Approved Methadyl Acetate The risk or severity of adverse effects can be increased when Protriptyline is combined with Methadyl Acetate. Approved, Illicit Methamphetamine Protriptyline may decrease the antihypertensive activities of Methamphetamine. Approved, Illicit Methapyrilene The risk or severity of adverse effects can be increased when Protriptyline is combined with Methapyrilene. Withdrawn Methaqualone The risk or severity of adverse effects can be increased when Protriptyline is combined with Methaqualone. Illicit, Withdrawn Methocarbamol The risk or severity of adverse effects can be increased when Protriptyline is combined with Methocarbamol. Approved, Vet Approved Methohexital The metabolism of Protriptyline can be increased when combined with Methohexital. Approved Methotrimeprazine Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. Approved, Investigational Methoxamine Protriptyline may increase the vasopressor activities of Methoxamine. Approved, Investigational Methoxyflurane The risk or severity of adverse effects can be increased when Protriptyline is combined with Methoxyflurane. Approved, Investigational, Vet Approved Methoxyphenamine Protriptyline may increase the stimulatory activities of Methoxyphenamine. Experimental Methsuximide The risk or severity of adverse effects can be increased when Protriptyline is combined with Methsuximide. Approved Methyldopa Protriptyline may decrease the antihypertensive activities of Methyldopa. Approved Methylecgonine The risk or severity of adverse effects can be increased when Protriptyline is combined with Methylecgonine. Experimental Methylene blue Protriptyline may increase the serotonergic activities of Methylene blue. Approved, Investigational Methylphenidate The risk or severity of adverse effects can be increased when Methylphenidate is combined with Protriptyline. Approved, Investigational Methylphenobarbital The metabolism of Protriptyline can be increased when combined with Methylphenobarbital. Approved Metoclopramide The risk or severity of adverse effects can be increased when Metoclopramide is combined with Protriptyline. Approved, Investigational Metoprolol The metabolism of Protriptyline can be decreased when combined with Metoprolol. Approved, Investigational Metyrosine The risk or severity of adverse effects can be increased when Metyrosine is combined with Protriptyline. Approved Midazolam The risk or severity of adverse effects can be increased when Midazolam is combined with Protriptyline. Approved, Illicit Midodrine Protriptyline may increase the vasopressor activities of Midodrine. Approved Midomafetamine Protriptyline may increase the stimulatory activities of Midomafetamine. Experimental, Illicit, Investigational Midostaurin The metabolism of Protriptyline can be decreased when combined with Midostaurin. Approved, Investigational Mifepristone Mifepristone may increase the QTc-prolonging activities of Protriptyline. Approved, Investigational Milnacipran The risk or severity of adverse effects can be increased when Protriptyline is combined with Milnacipran. Approved, Investigational Minaprine Minaprine may increase the serotonergic activities of Protriptyline. Approved Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Protriptyline. Approved, Investigational Mirabegron The metabolism of Protriptyline can be decreased when combined with Mirabegron. Approved Mirtazapine Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. Approved MMDA Protriptyline may increase the stimulatory activities of MMDA. Experimental, Illicit Moclobemide Moclobemide may increase the serotonergic activities of Protriptyline. Approved, Investigational Moexipril The serum concentration of Protriptyline can be increased when it is combined with Moexipril. Approved Molindone The risk or severity of adverse effects can be increased when Protriptyline is combined with Molindone. Approved Moperone The risk or severity of adverse effects can be increased when Protriptyline is combined with Moperone. Experimental Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Protriptyline. Approved, Investigational Mosapramine The risk or severity of adverse effects can be increased when Protriptyline is combined with Mosapramine. Experimental Moxifloxacin Protriptyline may increase the QTc-prolonging activities of Moxifloxacin. Approved, Investigational Moxonidine The therapeutic efficacy of Moxonidine can be decreased when used in combination with Protriptyline. Approved, Investigational N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline The serum concentration of Protriptyline can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline. Experimental Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Protriptyline. Approved, Investigational Nafamostat The serum concentration of Protriptyline can be increased when it is combined with Nafamostat. Approved, Investigational Nalbuphine The risk or severity of adverse effects can be increased when Nalbuphine is combined with Protriptyline. Approved Naloxegol The serum concentration of Naloxegol can be increased when it is combined with Protriptyline. Approved Naphazoline Protriptyline may decrease the antihypertensive activities of Naphazoline. Approved Naratriptan The risk or severity of adverse effects can be increased when Protriptyline is combined with Naratriptan. Approved, Investigational Nefazodone The risk or severity of adverse effects can be increased when Protriptyline is combined with Nefazodone. Approved, Withdrawn Nelfinavir The serum concentration of Protriptyline can be increased when it is combined with Nelfinavir. Approved Nevirapine The metabolism of Protriptyline can be decreased when combined with Nevirapine. Approved Nialamide Nialamide may increase the serotonergic activities of Protriptyline. Withdrawn Nicardipine The metabolism of Protriptyline can be decreased when combined with Nicardipine. Approved, Investigational Nicorandil Protriptyline may increase the hypotensive activities of Nicorandil. Approved, Investigational Nilotinib Protriptyline may increase the QTc-prolonging activities of Nilotinib. Approved, Investigational Nitrazepam The risk or severity of adverse effects can be increased when Nitrazepam is combined with Protriptyline. Approved Nitrous oxide The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Protriptyline. Approved, Vet Approved Nordazepam The risk or severity of adverse effects can be increased when Protriptyline is combined with Nordazepam. Approved Norepinephrine Protriptyline may decrease the antihypertensive activities of Norepinephrine. Approved Norflurane The risk or severity of adverse effects can be increased when Protriptyline is combined with Norflurane. Approved, Investigational Normethadone The risk or severity of adverse effects can be increased when Protriptyline is combined with Normethadone. Approved, Illicit Nortriptyline The risk or severity of adverse effects can be increased when Protriptyline is combined with Nortriptyline. Approved Octamoxin Octamoxin may increase the serotonergic activities of Protriptyline. Withdrawn Ofloxacin Protriptyline may increase the QTc-prolonging activities of Ofloxacin. Approved Olanzapine The risk or severity of adverse effects can be increased when Olanzapine is combined with Protriptyline. Approved, Investigational Olodaterol The risk or severity of adverse effects can be increased when Protriptyline is combined with Olodaterol. Approved Olopatadine The risk or severity of adverse effects can be increased when Protriptyline is combined with Olopatadine. Approved Omapatrilat The serum concentration of Protriptyline can be increased when it is combined with Omapatrilat. Investigational Ondansetron Protriptyline may increase the QTc-prolonging activities of Ondansetron. Approved Opium The risk or severity of adverse effects can be increased when Protriptyline is combined with Opium. Approved, Illicit Orciprenaline The risk or severity of adverse effects can be increased when Protriptyline is combined with Orciprenaline. Approved Orphenadrine Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. Approved Osanetant The risk or severity of adverse effects can be increased when Protriptyline is combined with Osanetant. Investigational Otamixaban The serum concentration of Protriptyline can be increased when it is combined with Otamixaban. Investigational Oxazepam The risk or severity of adverse effects can be increased when Oxazepam is combined with Protriptyline. Approved Oxprenolol The risk or severity of adverse effects can be increased when Protriptyline is combined with Oxprenolol. Approved Oxybuprocaine The risk or severity of adverse effects can be increased when Protriptyline is combined with Oxybuprocaine. Approved, Investigational Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Protriptyline. Approved, Illicit, Investigational Oxymetazoline Protriptyline may decrease the antihypertensive activities of Oxymetazoline. Approved, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Protriptyline. Approved, Investigational, Vet Approved Oxypertine The risk or severity of adverse effects can be increased when Protriptyline is combined with Oxypertine. Experimental Paliperidone Protriptyline may decrease the antihypertensive activities of Paliperidone. Approved Palonosetron Palonosetron may increase the serotonergic activities of Protriptyline. Approved, Investigational Panobinostat The serum concentration of Protriptyline can be increased when it is combined with Panobinostat. Approved, Investigational Paraldehyde Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. Approved, Investigational Pargyline Pargyline may increase the serotonergic activities of Protriptyline. Approved Paroxetine The risk or severity of adverse effects can be increased when Paroxetine is combined with Protriptyline. Approved, Investigational Pazopanib The serum concentration of Pazopanib can be increased when it is combined with Protriptyline. Approved Peginterferon alfa-2b The serum concentration of Protriptyline can be decreased when it is combined with Peginterferon alfa-2b. Approved Penfluridol The risk or severity of adverse effects can be increased when Protriptyline is combined with Penfluridol. Experimental Pentamidine Protriptyline may increase the QTc-prolonging activities of Pentamidine. Approved, Investigational Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Protriptyline. Approved, Vet Approved Pentobarbital The metabolism of Protriptyline can be increased when combined with Pentobarbital. Approved, Investigational, Vet Approved Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Protriptyline. Approved Perazine The risk or severity of adverse effects can be increased when Protriptyline is combined with Perazine. Approved, Investigational Perflutren Protriptyline may increase the QTc-prolonging activities of Perflutren. Approved Pergolide Protriptyline may decrease the antihypertensive activities of Pergolide. Approved, Investigational, Vet Approved, Withdrawn Perindopril The serum concentration of Protriptyline can be increased when it is combined with Perindopril. Approved Perospirone The risk or severity of adverse effects can be increased when Protriptyline is combined with Perospirone. Approved Perphenazine The risk or severity of adverse effects can be increased when Perphenazine is combined with Protriptyline. Approved Pethidine The risk or severity of adverse effects can be increased when Protriptyline is combined with Pethidine. Approved PF-00610355 The risk or severity of adverse effects can be increased when Protriptyline is combined with PF-00610355. Investigational Phenazocine The risk or severity of adverse effects can be increased when Protriptyline is combined with Phenazocine. Experimental Phendimetrazine Protriptyline may increase the vasopressor activities of Phendimetrazine. Approved, Illicit Phenelzine Phenelzine may increase the serotonergic activities of Protriptyline. Approved Phenibut The risk or severity of adverse effects can be increased when Protriptyline is combined with Phenibut. Experimental Phenindione Protriptyline may increase the anticoagulant activities of Phenindione. Approved, Investigational Pheniprazine Pheniprazine may increase the serotonergic activities of Protriptyline. Withdrawn Phenobarbital The metabolism of Protriptyline can be increased when combined with Phenobarbital. Approved, Investigational Phenoperidine The risk or severity of adverse effects can be increased when Protriptyline is combined with Phenoperidine. Experimental Phenoxyethanol The risk or severity of adverse effects can be increased when Protriptyline is combined with Phenoxyethanol. Approved Phenoxypropazine Phenoxypropazine may increase the serotonergic activities of Protriptyline. Withdrawn Phenprocoumon Protriptyline may increase the anticoagulant activities of Phenprocoumon. Approved, Investigational Phentermine Protriptyline may increase the stimulatory activities of Phentermine. Approved, Illicit Phenylephrine Protriptyline may increase the vasopressor activities of Phenylephrine. Approved Phenylpropanolamine The risk or severity of adverse effects can be increased when Protriptyline is combined with Phenylpropanolamine. Approved, Vet Approved, Withdrawn Phenytoin The risk or severity of adverse effects can be increased when Phenytoin is combined with Protriptyline. Approved, Vet Approved Phosphoramidon The serum concentration of Protriptyline can be increased when it is combined with Phosphoramidon. Experimental Pimozide Protriptyline may increase the QTc-prolonging activities of Pimozide. Approved Pipamperone The risk or severity of adverse effects can be increased when Protriptyline is combined with Pipamperone. Approved, Investigational Pipotiazine The risk or severity of adverse effects can be increased when Protriptyline is combined with Pipotiazine. Approved, Investigational Pirbuterol The risk or severity of adverse effects can be increased when Protriptyline is combined with Pirbuterol. Approved Piritramide The risk or severity of adverse effects can be increased when Protriptyline is combined with Piritramide. Approved, Investigational Pirlindole Pirlindole may increase the serotonergic activities of Protriptyline. Approved Pitolisant The therapeutic efficacy of Pitolisant can be decreased when used in combination with Protriptyline. Approved, Investigational Pivhydrazine Pivhydrazine may increase the serotonergic activities of Protriptyline. Withdrawn Pizotifen The risk or severity of adverse effects can be increased when Protriptyline is combined with Pizotifen. Approved Pomalidomide The risk or severity of adverse effects can be increased when Protriptyline is combined with Pomalidomide. Approved Pramipexole Protriptyline may increase the sedative activities of Pramipexole. Approved, Investigational Pramocaine The risk or severity of adverse effects can be increased when Protriptyline is combined with Pramocaine. Approved Prazepam The risk or severity of adverse effects can be increased when Protriptyline is combined with Prazepam. Approved, Illicit Pregabalin The therapeutic efficacy of Protriptyline can be increased when used in combination with Pregabalin. Approved, Illicit, Investigational Prilocaine The risk or severity of adverse effects can be increased when Protriptyline is combined with Prilocaine. Approved Primaquine Protriptyline may increase the QTc-prolonging activities of Primaquine. Approved Primidone The metabolism of Protriptyline can be increased when combined with Primidone. Approved, Vet Approved Prinomastat The serum concentration of Protriptyline can be increased when it is combined with Prinomastat. Investigational Procainamide Protriptyline may increase the QTc-prolonging activities of Procainamide. Approved Procaine Procaine may increase the serotonergic activities of Protriptyline. Approved, Investigational, Vet Approved Procarbazine Procarbazine may increase the serotonergic activities of Protriptyline. Approved, Investigational Procaterol The risk or severity of adverse effects can be increased when Protriptyline is combined with Procaterol. Approved, Investigational Prochlorperazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Protriptyline. Approved, Vet Approved Promazine The metabolism of Protriptyline can be decreased when combined with Promazine. Approved, Vet Approved Promethazine The risk or severity of adverse effects can be increased when Protriptyline is combined with Promethazine. Approved, Investigational Propafenone Protriptyline may increase the QTc-prolonging activities of Propafenone. Approved Propanidid The risk or severity of adverse effects can be increased when Protriptyline is combined with Propanidid. Experimental Proparacaine The risk or severity of adverse effects can be increased when Protriptyline is combined with Proparacaine. Approved, Vet Approved Propericiazine The risk or severity of adverse effects can be increased when Protriptyline is combined with Propericiazine. Approved, Investigational Propofol The risk or severity of adverse effects can be increased when Propofol is combined with Protriptyline. Approved, Investigational, Vet Approved Propoxycaine The risk or severity of adverse effects can be increased when Protriptyline is combined with Propoxycaine. Approved Prothipendyl The risk or severity of adverse effects can be increased when Protriptyline is combined with Prothipendyl. Investigational Protokylol The risk or severity of adverse effects can be increased when Protriptyline is combined with Protokylol. Approved, Vet Approved Proxibarbal The risk or severity of adverse effects can be increased when Protriptyline is combined with Proxibarbal. Experimental Prucalopride The serum concentration of Prucalopride can be increased when it is combined with Protriptyline. Approved PSD502 The risk or severity of adverse effects can be increased when Protriptyline is combined with PSD502. Investigational Pseudoephedrine Protriptyline may decrease the antihypertensive activities of Pseudoephedrine. Approved Quazepam The risk or severity of adverse effects can be increased when Quazepam is combined with Protriptyline. Approved, Illicit Quetiapine Protriptyline may increase the QTc-prolonging activities of Quetiapine. Approved Quinapril The serum concentration of Protriptyline can be increased when it is combined with Quinapril. Approved, Investigational Quinidine Protriptyline may increase the QTc-prolonging activities of Quinidine. Approved, Investigational Quinine Protriptyline may increase the QTc-prolonging activities of Quinine. Approved Quinisocaine The risk or severity of adverse effects can be increased when Protriptyline is combined with Quinisocaine. Experimental Racecadotril The serum concentration of Protriptyline can be increased when it is combined with Racecadotril. Investigational Racepinephrine Protriptyline may decrease the antihypertensive activities of Racepinephrine. Approved Raclopride The risk or severity of adverse effects can be increased when Protriptyline is combined with Raclopride. Investigational Ramelteon The risk or severity of adverse effects can be increased when Protriptyline is combined with Ramelteon. Approved, Investigational Ramipril The serum concentration of Protriptyline can be increased when it is combined with Ramipril. Approved Ranolazine The serum concentration of Ranolazine can be increased when it is combined with Protriptyline. Approved, Investigational Rasagiline Rasagiline may increase the serotonergic activities of Protriptyline. Approved Remifentanil The risk or severity of adverse effects can be increased when Remifentanil is combined with Protriptyline. Approved Remikiren The serum concentration of Protriptyline can be increased when it is combined with Remikiren. Approved Remoxipride The risk or severity of adverse effects can be increased when Protriptyline is combined with Remoxipride. Approved, Withdrawn Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Protriptyline. Approved, Investigational Rifaximin The serum concentration of Rifaximin can be increased when it is combined with Protriptyline. Approved, Investigational Risperidone Protriptyline may decrease the antihypertensive activities of Risperidone. Approved, Investigational Ritanserin The risk or severity of adverse effects can be increased when Protriptyline is combined with Ritanserin. Investigational Ritobegron Protriptyline may increase the stimulatory activities of Ritobegron. Investigational Ritodrine The risk or severity of adverse effects can be increased when Protriptyline is combined with Ritodrine. Approved, Investigational Ritonavir The metabolism of Protriptyline can be decreased when combined with Ritonavir. Approved, Investigational Rivaroxaban The serum concentration of Protriptyline can be increased when it is combined with Rivaroxaban. Approved Rizatriptan The risk or severity of adverse effects can be increased when Protriptyline is combined with Rizatriptan. Approved Rolapitant The metabolism of Protriptyline can be decreased when combined with Rolapitant. Approved, Investigational Romifidine Protriptyline may decrease the antihypertensive activities of Romifidine. Vet Approved Ropinirole Protriptyline may increase the sedative activities of Ropinirole. Approved, Investigational Ropivacaine The risk or severity of adverse effects can be increased when Protriptyline is combined with Ropivacaine. Approved Rotigotine Protriptyline may increase the sedative activities of Rotigotine. Approved Rucaparib The metabolism of Protriptyline can be decreased when combined with Rucaparib. Approved, Investigational Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Protriptyline. Approved S-3304 The serum concentration of Protriptyline can be increased when it is combined with S-3304. Investigational Safrazine Safrazine may increase the serotonergic activities of Protriptyline. Withdrawn Salbutamol The risk or severity of adverse effects can be increased when Protriptyline is combined with Salbutamol. Approved, Vet Approved Salmeterol The risk or severity of adverse effects can be increased when Protriptyline is combined with Salmeterol. Approved Saquinavir The serum concentration of Protriptyline can be increased when it is combined with Saquinavir. Approved, Investigational Saxagliptin The serum concentration of Protriptyline can be increased when it is combined with Saxagliptin. Approved Scopolamine The risk or severity of adverse effects can be increased when Protriptyline is combined with Scopolamine. Approved, Investigational Secobarbital The metabolism of Protriptyline can be increased when combined with Secobarbital. Approved, Vet Approved Selegiline Selegiline may increase the serotonergic activities of Protriptyline. Approved, Investigational, Vet Approved Sepranolone The risk or severity of adverse effects can be increased when Protriptyline is combined with Sepranolone. Investigational Sertindole The risk or severity of adverse effects can be increased when Protriptyline is combined with Sertindole. Approved, Investigational, Withdrawn Sertraline The risk or severity of adverse effects can be increased when Sertraline is combined with Protriptyline. Approved Sevoflurane The risk or severity of adverse effects can be increased when Sevoflurane is combined with Protriptyline. Approved, Vet Approved Silodosin The serum concentration of Silodosin can be increased when it is combined with Protriptyline. Approved Simeprevir The serum concentration of Protriptyline can be increased when it is combined with Simeprevir. Approved Sitagliptin The serum concentration of Protriptyline can be increased when it is combined with Sitagliptin. Approved, Investigational Sivelestat The serum concentration of Protriptyline can be increased when it is combined with Sivelestat. Investigational Sodium oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Protriptyline. Approved Sodium phosphate, monobasic The risk or severity of adverse effects can be increased when Protriptyline is combined with Sodium phosphate. Approved Sotalol Protriptyline may increase the QTc-prolonging activities of Sotalol. Approved Spirapril The serum concentration of Protriptyline can be increased when it is combined with Spirapril. Approved St. John's Wort The metabolism of Protriptyline can be increased when combined with St. John's Wort. Approved, Investigational, Nutraceutical Stiripentol The metabolism of Protriptyline can be decreased when combined with Stiripentol. Approved Sufentanil The risk or severity of adverse effects can be increased when Sufentanil is combined with Protriptyline. Approved, Investigational Sulfisoxazole Protriptyline may increase the QTc-prolonging activities of Sulfisoxazole. Approved, Vet Approved Sulpiride The risk or severity of adverse effects can be increased when Protriptyline is combined with Sulpiride. Approved, Investigational Sultopride The risk or severity of adverse effects can be increased when Protriptyline is combined with Sultopride. Experimental Sumatriptan The risk or severity of adverse effects can be increased when Protriptyline is combined with Sumatriptan. Approved, Investigational Suvorexant Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. Approved, Investigational Tandospirone The risk or severity of adverse effects can be increased when Protriptyline is combined with Tandospirone. Investigational Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Protriptyline. Approved Tasimelteon The risk or severity of adverse effects can be increased when Protriptyline is combined with Tasimelteon. Approved, Investigational Tedizolid Phosphate Tedizolid Phosphate may increase the serotonergic activities of Protriptyline. Approved Telaprevir The serum concentration of Protriptyline can be increased when it is combined with Telaprevir. Approved, Withdrawn Telavancin Protriptyline may increase the QTc-prolonging activities of Telavancin. Approved Telithromycin Protriptyline may increase the QTc-prolonging activities of Telithromycin. Approved Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Protriptyline. Approved, Investigational Temocapril The serum concentration of Protriptyline can be increased when it is combined with Temocapril. Experimental, Investigational Terbinafine The metabolism of Protriptyline can be decreased when combined with Terbinafine. Approved, Investigational, Vet Approved Terbutaline The risk or severity of adverse effects can be increased when Protriptyline is combined with Terbutaline. Approved Tetrabenazine Protriptyline may increase the QTc-prolonging activities of Tetrabenazine. Approved, Investigational Tetracaine The risk or severity of adverse effects can be increased when Protriptyline is combined with Tetracaine. Approved, Vet Approved Tetrahydropalmatine The risk or severity of adverse effects can be increased when Protriptyline is combined with Tetrahydropalmatine. Investigational Tetrodotoxin The risk or severity of adverse effects can be increased when Protriptyline is combined with Tetrodotoxin. Investigational Tetryzoline Protriptyline may increase the vasopressor activities of Tetryzoline. Approved Thalidomide Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. Approved, Investigational, Withdrawn Thiamylal The metabolism of Protriptyline can be increased when combined with Thiamylal. Approved, Vet Approved Thiopental The metabolism of Protriptyline can be increased when combined with Thiopental. Approved, Vet Approved Thiopropazate The risk or severity of adverse effects can be increased when Protriptyline is combined with Thiopropazate. Experimental Thioproperazine The risk or severity of adverse effects can be increased when Protriptyline is combined with Thioproperazine. Approved Thioridazine The metabolism of Protriptyline can be decreased when combined with Thioridazine. Approved, Withdrawn Thiorphan The serum concentration of Protriptyline can be increased when it is combined with Thiorphan. Experimental Thiothixene The risk or severity of adverse effects can be increased when Thiothixene is combined with Protriptyline. Approved Thyroid, porcine Thyroid, porcine may increase the arrhythmogenic activities of Protriptyline. Approved Tiagabine The risk or severity of adverse effects can be increased when Protriptyline is combined with Tiagabine. Approved, Investigational Tiapride The risk or severity of adverse effects can be increased when Protriptyline is combined with Tiapride. Approved, Investigational Ticlopidine The metabolism of Protriptyline can be decreased when combined with Ticlopidine. Approved Tiletamine The risk or severity of adverse effects can be increased when Protriptyline is combined with Tiletamine. Vet Approved Tilidine The risk or severity of adverse effects can be increased when Protriptyline is combined with Tilidine. Experimental Tioclomarol Protriptyline may increase the anticoagulant activities of Tioclomarol. Experimental Tipranavir The metabolism of Protriptyline can be decreased when combined with Tipranavir. Approved, Investigational Tizanidine Protriptyline may decrease the antihypertensive activities of Tizanidine. Approved, Investigational Tolcapone The risk or severity of adverse effects can be increased when Tolcapone is combined with Protriptyline. Approved, Withdrawn Toloxatone Toloxatone may increase the serotonergic activities of Protriptyline. Approved Topiramate The risk or severity of adverse effects can be increased when Topiramate is combined with Protriptyline. Approved Topotecan The serum concentration of Topotecan can be increased when it is combined with Protriptyline. Approved, Investigational Toremifene Protriptyline may increase the QTc-prolonging activities of Toremifene. Approved, Investigational Tramadol Protriptyline may increase the neuroexcitatory activities of Tramadol. Approved, Investigational Trandolapril The serum concentration of Protriptyline can be increased when it is combined with Trandolapril. Approved Tranylcypromine Tranylcypromine may increase the serotonergic activities of Protriptyline. Approved, Investigational Trazodone The risk or severity of adverse effects can be increased when Trazodone is combined with Protriptyline. Approved, Investigational Triazolam The risk or severity of adverse effects can be increased when Triazolam is combined with Protriptyline. Approved, Investigational Tricaine methanesulfonate The risk or severity of adverse effects can be increased when Protriptyline is combined with Tricaine methanesulfonate. Vet Approved Trichloroethylene The risk or severity of adverse effects can be increased when Protriptyline is combined with Trichloroethylene. Approved Trifluoperazine The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Protriptyline. Approved, Investigational Trifluperidol The risk or severity of adverse effects can be increased when Protriptyline is combined with Trifluperidol. Experimental Triflupromazine The risk or severity of adverse effects can be increased when Protriptyline is combined with Triflupromazine. Approved, Vet Approved Trimipramine The risk or severity of adverse effects can be increased when Protriptyline is combined with Trimipramine. Approved Triprolidine The risk or severity of adverse effects can be increased when Protriptyline is combined with Triprolidine. Approved Tropisetron Tropisetron may increase the serotonergic activities of Protriptyline. Approved, Investigational Ubenimex The serum concentration of Protriptyline can be increased when it is combined with Ubenimex. Experimental, Investigational Ulinastatin The serum concentration of Protriptyline can be increased when it is combined with Ulinastatin. Investigational Valproic Acid The serum concentration of Protriptyline can be increased when it is combined with Valproic Acid. Approved, Investigational Vandetanib Protriptyline may increase the QTc-prolonging activities of Vandetanib. Approved Vemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Protriptyline. Approved Venlafaxine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Protriptyline. Approved Veralipride The risk or severity of adverse effects can be increased when Protriptyline is combined with Veralipride. Experimental Vigabatrin The risk or severity of adverse effects can be increased when Protriptyline is combined with Vigabatrin. Approved Vilanterol The risk or severity of adverse effects can be increased when Protriptyline is combined with Vilanterol. Approved Vilazodone The risk or severity of adverse effects can be increased when Vilazodone is combined with Protriptyline. Approved Vildagliptin The serum concentration of Protriptyline can be increased when it is combined with Vildagliptin. Approved, Investigational Vincristine The excretion of Vincristine can be decreased when combined with Protriptyline. Approved, Investigational Vinyl ether The risk or severity of adverse effects can be increased when Protriptyline is combined with Vinyl ether. Experimental Vortioxetine The risk or severity of adverse effects can be increased when Vortioxetine is combined with Protriptyline. Approved, Investigational Warfarin Protriptyline may increase the anticoagulant activities of Warfarin. Approved Xenon The risk or severity of adverse effects can be increased when Protriptyline is combined with Xenon. Experimental Ximelagatran The serum concentration of Protriptyline can be increased when it is combined with Ximelagatran. Approved, Investigational, Withdrawn Xylazine Protriptyline may decrease the antihypertensive activities of Xylazine. Vet Approved Xylometazoline Protriptyline may decrease the antihypertensive activities of Xylometazoline. Approved, Investigational Yohimbine The serum concentration of Yohimbine can be increased when it is combined with Protriptyline. Approved, Investigational, Vet Approved Z-Val-Ala-Asp fluoromethyl ketone The serum concentration of Protriptyline can be increased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone. Experimental Zaleplon The risk or severity of adverse effects can be increased when Zaleplon is combined with Protriptyline. Approved, Illicit, Investigational Ziconotide The risk or severity of adverse effects can be increased when Protriptyline is combined with Ziconotide. Approved Zimelidine The risk or severity of adverse effects can be increased when Protriptyline is combined with Zimelidine. Withdrawn Ziprasidone Protriptyline may increase the QTc-prolonging activities of Ziprasidone. Approved Zofenopril The serum concentration of Protriptyline can be increased when it is combined with Zofenopril. Experimental Zolazepam The risk or severity of adverse effects can be increased when Protriptyline is combined with Zolazepam. Vet Approved Zolmitriptan The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Protriptyline. Approved, Investigational Zolpidem Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Approved Zonisamide The risk or severity of adverse effects can be increased when Protriptyline is combined with Zonisamide. Approved, Investigational Zopiclone The risk or severity of adverse effects can be increased when Zopiclone is combined with Protriptyline. Approved Zotepine The risk or severity of adverse effects can be increased when Protriptyline is combined with Zotepine. Approved, Investigational, Withdrawn Zuclopenthixol Protriptyline may increase the QTc-prolonging activities of Zuclopenthixol. Approved, Investigational - Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0014488
- KEGG Compound
- C07408
- PubChem Compound
- 4976
- PubChem Substance
- 46505128
- ChemSpider
- 4805
- BindingDB
- 50176062
- ChEBI
- 8597
- ChEMBL
- CHEMBL668
- Therapeutic Targets Database
- DAP000863
- PharmGKB
- PA451168
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Protriptyline
- ATC Codes
- N06AA11 — Protriptyline
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count Not Available Completed Treatment Depression 1
Pharmacoeconomics
- Manufacturers
- Sanofi aventis us llc
- Pfizer laboratories div pfizer inc
- Roxane laboratories inc
- Sigmapharm laboratories llc
- Odyssey pharmaceuticals inc
- Packagers
- Barr Pharmaceuticals
- Duramed
- Mallinckrodt Inc.
- Pliva Inc.
- Qualitest
- Rising Pharmaceuticals
- Roxane Labs
- Sanofi-Aventis Inc.
- Dosage forms
Form Route Strength Tablet Oral 10 mg/1 Tablet Oral 5 mg/1 Tablet, film coated Oral 10 mg/1 Tablet, film coated Oral 5 mg/1 Tablet Oral 10 mg - Prices
Unit description Cost Unit Tofranil-PM 30 125 mg capsule Bottle 588.33USD bottle Tofranil-PM 30 150 mg capsule Bottle 588.33USD bottle Tofranil-PM 30 75 mg capsule Bottle 588.33USD bottle Tofranil 30 50 mg tablet Bottle 185.09USD bottle Tofranil-pm 100 mg capsule 19.23USD capsule Tofranil-pm 150 mg capsule 18.86USD capsule Tofranil-pm 75 mg capsule 18.86USD capsule Tofranil-pm 125 mg capsule 18.68USD capsule Anafranil 25 mg capsule 13.51USD capsule Anafranil 50 mg capsule 13.51USD capsule Anafranil 75 mg capsule 13.24USD capsule Tofranil 50 mg tablet 6.64USD tablet Norpramin 150 mg tablet 6.23USD tablet Surmontil 100 mg capsule 5.92USD capsule Tofranil 25 mg tablet 4.97USD tablet Tofranil 10 mg tablet 4.73USD tablet Norpramin 100 mg tablet 4.27USD tablet Surmontil 50 mg capsule 4.15USD capsule Vivactil 10 mg tablet 4.05USD tablet Norpramin 75 mg tablet 3.27USD tablet Protriptyline hcl 10 mg tablet 3.07USD tablet Vivactil 5 mg tablet 2.86USD tablet Norpramin 50 mg tablet 2.59USD tablet Surmontil 25 mg capsule 2.49USD capsule Protriptyline hcl 5 mg tablet 2.12USD tablet Norpramin 25 mg tablet 1.4USD tablet Norpramin 10 mg tablet 1.16USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 169-171 °C (Protriptyline HCl) Not Available water solubility 1.04 mg/L Not Available logP 4.7 Not Available - Predicted Properties
Property Value Source Water Solubility 0.000231 mg/mL ALOGPS logP 4.65 ALOGPS logP 4.5 ChemAxon logS -6.1 ALOGPS pKa (Strongest Basic) 10.54 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 1 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 12.03 Å2 ChemAxon Rotatable Bond Count 4 ChemAxon Refractivity 87.3 m3·mol-1 ChemAxon Polarizability 31.6 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9862 Caco-2 permeable + 0.7821 P-glycoprotein substrate Substrate 0.7406 P-glycoprotein inhibitor I Inhibitor 0.8563 P-glycoprotein inhibitor II Inhibitor 0.5597 Renal organic cation transporter Inhibitor 0.6622 CYP450 2C9 substrate Non-substrate 0.7206 CYP450 2D6 substrate Substrate 0.9034 CYP450 3A4 substrate Substrate 0.5285 CYP450 1A2 substrate Non-inhibitor 0.7595 CYP450 2C9 inhibitor Non-inhibitor 0.9071 CYP450 2D6 inhibitor Inhibitor 0.8933 CYP450 2C19 inhibitor Non-inhibitor 0.9026 CYP450 3A4 inhibitor Inhibitor 0.641 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.7512 Ames test Non AMES toxic 0.6 Carcinogenicity Non-carcinogens 0.9322 Biodegradation Not ready biodegradable 0.7732 Rat acute toxicity 3.0087 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.736 hERG inhibition (predictor II) Inhibitor 0.8132
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Mass Spectrum (Electron Ionization) MS splash10-006x-8910000000-ec599ee02d998905757e Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as dibenzocycloheptenes. These are compounds containing a dibenzocycloheptene moiety, which consists of two benzene rings connected by a cycloheptene ring.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Dibenzocycloheptenes
- Sub Class
- Not Available
- Direct Parent
- Dibenzocycloheptenes
- Alternative Parents
- Aralkylamines / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives
- Substituents
- Dibenzocycloheptene / Aralkylamine / Secondary amine / Secondary aliphatic amine / Organic nitrogen compound / Organopnictogen compound / Hydrocarbon derivative / Organonitrogen compound / Amine / Aromatic homopolycyclic compound
- Molecular Framework
- Aromatic homopolycyclic compounds
- External Descriptors
- organic tricyclic compound (CHEBI:8597)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Norepinephrine:sodium symporter activity
- Specific Function
- Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
- Gene Name
- SLC6A2
- Uniprot ID
- P23975
- Uniprot Name
- Sodium-dependent noradrenaline transporter
- Molecular Weight
- 69331.42 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
- Cheetham SC, Viggers JA, Butler SA, Prow MR, Heal DJ: [3H]nisoxetine--a radioligand for noradrenaline reuptake sites: correlation with inhibition of [3H]noradrenaline uptake and effect of DSP-4 lesioning and antidepressant treatments. Neuropharmacology. 1996 Jan;35(1):63-70. [PubMed:8684598]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Serotonin:sodium symporter activity
- Specific Function
- Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
- Gene Name
- SLC6A4
- Uniprot ID
- P31645
- Uniprot Name
- Sodium-dependent serotonin transporter
- Molecular Weight
- 70324.165 Da
References
- McDougle CJ, Epperson CN, Price LH, Gelernter J: Evidence for linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and obsessive compulsive disorder. Mol Psychiatry. 1998 May;3(3):270-3. [PubMed:9672904]
- Rouillon F, Blachier C, Dreyfus JP, Bouhassira M, Allicar MP: [Pharmaco-epidemiologic study of the use of antidepressant drugs in the general population]. Encephale. 1996 May;22 Spec No 1:39-48. [PubMed:8767026]
- Frazer A, Daws LC: Serotonin transporter function in vivo: assessment by chronoamperometry. Ann N Y Acad Sci. 1998 Dec 15;861:217-29. [PubMed:9928259]
- Daws LC, Toney GM, Gerhardt GA, Frazer A: In vivo chronoamperometric measures of extracellular serotonin clearance in rat dorsal hippocampus: contribution of serotonin and norepinephrine transporters. J Pharmacol Exp Ther. 1998 Aug;286(2):967-76. [PubMed:9694957]
- Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
- Kovachich GB, Aronson CE, Brunswick DJ: Effect of repeated administration of antidepressants on serotonin uptake sites in limbic and neocortical structures of rat brain determined by quantitative autoradiography. Neuropsychopharmacology. 1992 Dec;7(4):317-24. [PubMed:1476595]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
- Gene Name
- CYP2D6
- Uniprot ID
- P10635
- Uniprot Name
- Cytochrome P450 2D6
- Molecular Weight
- 55768.94 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- Molecular Weight
- 141477.255 Da
References
- Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A: Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000 Dec;295(3):1276-83. [PubMed:11082465]
Drug created on June 13, 2005 07:24 / Updated on July 02, 2018 20:42